JPMorgan subsidiary discloses share sale in Kangji Medical privatization

On November 5, 2025, a public disclosure form indicated that J.P. Morgan Securities PLC, an associate connected with the offeror in the Kangji Medical Holdings Limited privatization, executed a securities dealing. The transaction, dated November 4, 2025, involved the sale of 1,000 shares described as "other types of securities (e.g. equity swaps)." This dealing was specifically for hedging Delta 1 products resulting from wholly unsolicited client-driven orders.

The sale generated a total amount received of $9,040.00. Both the highest and lowest prices received for these shares were $9.04. The disclosure was made pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers, highlighting J.P. Morgan Securities PLC's role in the ongoing scheme of arrangement.

J.P. Morgan Securities PLC confirmed that these dealings were made for its own account and that the entity is ultimately owned by JPMorgan Chase & Co. This disclosure provides transparency regarding significant transactions by associated parties during the privatization process of Kangji Medical Holdings Limited.